Sai Life Sciences Ltd: India's Emerging CRDMO Champion — Premium Multiple, Proven Trajectory

NSE: SAILIFE | BSE: 544307 | Sector: Healthcare (Pharma – CRDMO) | CMP: ₹1,218.90 | Market Cap: ₹25,854.72 Cr

Sai Life Sciences Ltd has quietly built itself into one of the most credible Indian contract research, development and manufacturing organisations (CRDMOs) and the post-listing market has noticed. The stock trades at ₹1,218.90 with a market capitalisation of ₹25,854.72 Cr, putting it firmly in the mid-cap league and roughly in the same orbit as the established peer Syngene International. With a trailing P/E of 75.61x, P/B of 10.0x, ROE of 14.0% and a one-year stock return of 58.2%, Sai Life is being re-rated as a structural growth play on global pharma outsourcing. This report dissects the business, the eight-quarter run-rate, the multi-year financial record, the peer set, the shareholding base anchored by global private equity, the DCF math, the risks and what all of it means for an investor sizing a position today.

1. Business Overview

Sai Life Sciences Ltd is a Hyderabad-headquartered, integrated Contract Research, Development and Manufacturing Organization (CRDMO) serving the global pharmaceutical and biotechnology industry. Incorporated in 1999, the company operates across the full drug-development lifecycle, from early-stage discovery and process chemistry to clinical-phase active pharmaceutical ingredient (API) manufacturing and commercial-scale production. The business model is structured around three interlocking service platforms — discovery, development and manufacturing — that allow Sai Life to walk with a customer molecule from the bench through to commercial supply.

The discovery arm offers medicinal chemistry, biology, in-vitro ADME, in-vivo pharmacology and integrated drug-discovery services. The development and manufacturing services cover process research, custom synthesis, analytical method development, clinical supply, HPAPI (high-potency API) manufacture, peptide synthesis and small-to-large-scale commercial API production. Crucially, the manufacturing footprint includes US FDA-inspected facilities, peptide blocks and high-containment capabilities — all of which are gating credentials for innovator pharma customers in regulated markets.

The clientele is a who's who of global pharma. Sai Life counts among its long-term customers several top-20 innovator companies in the US, Europe and Japan. According to the company's disclosures and analyst commentary, the business derives a meaningful share of revenue from a small group of strategic accounts — a typical pattern in the CDMO industry where trust and quality systems are built molecule-by-molecule over multi-year engagements. The recurring, multi-year nature of these programs is what gives CRDMOs their earnings visibility and the basis for premium valuations in the public markets.

From a capacity standpoint, the company has been on a multi-year capex cycle. Gross fixed assets have grown from ₹373 Cr in FY19 to ₹1,705 Cr in FY26 (per Screener.in's standalone balance sheet), with capital work-in-progress of ₹270 Cr as of March 2026. That capex is funding new API blocks, a greenfield peptide facility, HPAPI expansion and a brownfield injectables play. The total asset base has expanded from ₹1,212 Cr in FY19 to ₹3,603 Cr in FY26 — a 2.97x build-up in seven years that explains the rising depreciation line and the gradual operating-leverage thesis.

Operationally, Sai Life is led by a professional management team with deep pharma-services experience. Founder-promoter Krishna Kanumuri and CEO Suhasini Mohanty (former CEO of the CRAM business) anchor the leadership. The board includes representation from TPG (which holds a meaningful pre-IPO stake), and the company completed its main-board listing in 2024, ending a long stint as a private, TPG-backed business. The transition from a private-equity-owned firm to a listed entity has lifted governance disclosures, capital allocation transparency and analyst coverage.

In revenue terms, the company clocked ₹2,153 Cr in FY26 (standalone basis) — up from ₹695 Cr in FY19 — a 3.10x sales expansion over seven years. Net profit of ₹341 Cr in FY26 versus ₹73 Cr in FY19 is a 4.67x jump. The compounding has been especially sharp in the most recent three years, and the next section shows exactly how step-function-like the trajectory has become. Sai Life today employs thousands of scientists and operates a global footprint with subsidiaries and representative offices in the US, Europe and Japan — necessary infrastructure for an export-heavy CDMO whose customer meetings still happen in Boston, Basel and Tokyo.

In short, the business is a genuine, scaled, US-FDA-audited Indian CRDMO, sitting at the intersection of three powerful tailwinds — patent-cliff-driven outsourcing, the China+1 reshoring of API supply, and the rise of Indian innovation-services. The remaining question is whether the public-market multiple has already discounted the upside or whether the operating leverage has further to run.

Company Snapshot Table

2. Latest Quarter Deep Dive — Q4 FY26 and the Eight-Quarter Run-Rate

The standalone quarterly sequence tells the most important story in the Sai Life thesis. Below is the eight-quarter table (Screener.in, standalone basis, ₹ in Crores) for the period from Q3 FY24 (Dec 2023) through Q4 FY26 (Mar 2026). The data is extracted from the company's audited financial results filed with the exchanges.

Eight-Quarter Standalone Results Table

(Q1 FY25 Jun 2024 was the seasonal trough — a one-time inventory and client-mix issue that drove a 9% OPM and a small loss.)

Reading across this table, the post-IPO operational ramp is unmistakable. Sales have moved from a ₹373 Cr quarterly run-rate in Q3 FY24 to ₹594 Cr in Q4 FY26 — a 59% jump in just six quarters and a +₹221 Cr absolute increase. The corresponding operating profit expanded from ₹94 Cr to ₹168 Cr (+79%), and net profit climbed from ₹40 Cr to ₹103 Cr — a 2.58x jump. The standout quarter is Q3 FY26 (Dec 2025), where Sai Life posted a 33% OPM and a ₹179 Cr operating profit — its highest quarterly OPM in the eight-quarter window — on the back of better product mix, a richer set of commercial supply programs and a more efficient cost structure.

Sequential momentum in Q4 FY26: Sales of ₹594 Cr were up 8.2% QoQ from ₹549 Cr in Q3 FY26. Operating profit at ₹168 Cr was down 6.1% QoQ versus a strong ₹179 Cr in Q3 FY26 — the dip is explained by a 400bps seasonal step-down in OPM (from 33% to 28%) which is normal for the March quarter given employee increments and certain project close-outs. Other income of ₹16 Cr (versus ₹0 Cr in Q3 FY26) was a tailwind. Interest cost of ₹6 Cr is now an eighth of where it was eight quarters back (₹22 Cr in Dec 2023), reflecting the deleveraging from ₹869 Cr in FY23 to ₹223 Cr in FY26 — a 74% reduction in gross borrowings. Net profit of ₹103 Cr in Q4 FY26 is the highest in the eight-quarter table and was up 5.2% QoQ.

Year-on-year comparison (Q4 FY26 vs Q4 FY25): Sales grew 4.8% YoY (₹594 Cr vs ₹567 Cr), operating profit grew 9.1% YoY (₹168 Cr vs ₹154 Cr), and net profit grew 14.4% YoY (₹103 Cr vs ₹90 Cr). The margin story is the most attractive: net margin in Q4 FY26 at 17.3% versus 15.9% in Q4 FY25. The depreciation line has expanded from ₹28 Cr to ₹41 Cr YoY, consistent with the larger fixed asset base.

H1 vs H2 FY26 trajectory: The first half of FY26 delivered ₹1,010 Cr of sales and ₹141 Cr of net profit, while the second half delivered ₹1,143 Cr of sales and ₹201 Cr of net profit. H2 was 13.2% larger in sales and 42.6% larger in net profit — a textbook demonstration of operating leverage as the year progresses and fixed costs are spread over higher volumes. Full-year FY26 sales of ₹2,153 Cr and net profit of ₹341 Cr place the business on a ₹2,400-2,500 Cr revenue trajectory for FY27 if growth continues in the mid-to-high teens.

Key quality of earnings observations:

• CFO/OP ratio of 89% in FY26 (cash from operations of ₹495 Cr versus operating profit of approximately ₹600 Cr ex-other income), indicating strong cash conversion and limited receivables bloat.
• Working capital days of 76 in FY26 versus 20 in FY24 — there is a working-capital build, but it is mostly inventory and capex-related, not bad-debt-related.
• Tax rate normalised at 25% — the company has moved out of the 30% historical band, in line with the lower corporate-tax regime.

The eight-quarter read-through is unambiguous: Sai Life is on a mid-twenties revenue CAGR and a 40-50% profit CAGR run-rate. The Q1 FY25 blip is the only stain on the print and is a one-time inventory adjustment, not a structural concern. As the company progresses into FY27 with new capacity coming online and a richer product mix, the sequential momentum should logically sustain — provided of course the global pharma R&D environment remains accommodative.

3. Financial Performance — 5-Year Overview (FY22 to FY26)

While the quarterly chart is the most current, the five-year financial record is what institutional investors look at to confirm that a growth run is durable and not a flash in the pan. The Screener.in standalone data gives us FY22 through FY26 in clean form. (Earlier years are also shown in the data table for additional context.)

Five-Year Standalone P&L Summary Table

EPS calculated as Net Profit / Equity Capital. Equity capital moved from ₹18 Cr (FY22-FY24) to ₹21 Cr post the 2024 IPO. EPS shown is standalone.

Revenue analysis: Sales have grown from ₹841 Cr in FY22 to ₹2,153 Cr in FY26 — a 2.56x increase, or a 27% CAGR. The growth was somewhat back-loaded: FY22 to FY23 was a +38% jump, FY23 to FY24 was +23%, FY24 to FY25 was +16%, and FY25 to FY26 was a strong +31%. The acceleration in FY26 is the proof-point that the post-IPO capex is bearing fruit, with new manufacturing capacity ramping and incremental high-margin commercial API business coming on-stream.

Margin analysis: Operating profit margins have expanded from a trough of 14% in FY23 to 28% in FY26 — a 1,400bps improvement. Two factors drive this. First, mix shift towards higher-value-added CDMO services (discovery, complex chemistry, HPAPIs, peptides) where unit economics are better. Second, operating leverage on the new fixed assets. The corollary is that the OPM trajectory is the central pillar of the bull thesis: every additional ₹100 Cr of sales now drops disproportionately to operating profit because a larger share is recurring commercial manufacturing and not discovery subsidisation.

Profitability analysis: Net profit of ₹341 Cr in FY26 is a 21.3x jump from ₹16 Cr in FY22 — a 114% CAGR. The non-linearity of this print (versus the more orderly 27% sales CAGR) is what triggers the optical valuation heat. Note that the FY22-FY23 net profit was depressed by the higher interest burden and elevated depreciation from the capex cycle. With interest costs now at ₹33 Cr versus ₹81 Cr in FY24, the drag has reversed — interest is now an enabler, not a detractor.

Return ratios: ROE of 14.0% in FY26 is the highest in the five-year window but is still below the levels of pure-play API companies. Three reasons: (a) the IPO capital of approximately ₹1,150 Cr raised in 2024 inflated the equity base from ₹1,011 Cr (FY24) to ₹2,168 Cr (FY25), mathematically compressing ROE; (b) Sai Life is still in capex deployment mode so the marginal capital has not yet earned through; and (c) the company has a 0% dividend payout, retaining all cash for growth. As the post-IPO capital earns its cost of equity, ROE should logically drift back to the 18-20% zone in the medium term. ROCE of 19.2% in FY26 is healthier and underscores the underlying asset productivity.

Cash flow: Cash from operations of ₹495 Cr in FY26 (versus ₹330 Cr in FY25) is a +50% jump and is more than sufficient to fund the ₹393 Cr investing outflow. This is the first time in five years that Sai Life has effectively funded its capex from internal accruals — a meaningful inflection. The negative free cash flow of ₹-94 Cr in FY26 is much improved from ₹-565 Cr in FY25 (which had absorbed the IPO funds deployment). The CFO/OP ratio of 89% is best-in-class for a CDMO.

Working capital and balance sheet: Reserves have grown from ₹873 Cr (FY22) to ₹2,487 Cr (FY26) — a 2.85x build. Total assets of ₹3,603 Cr are funded by ₹223 Cr of debt, ₹872 Cr of other liabilities, and ₹2,508 Cr of equity — giving a debt-to-equity ratio of 0.09x. Sai Life is now essentially a debt-free company, a structural change from FY23 when the D/E ratio was 0.95x. This de-leveraging was funded primarily by the IPO proceeds and is the single most important balance-sheet change in the five-year window.

In summary, FY26 was a milestone year: highest-ever sales, highest-ever operating profit, highest-ever net profit, lowest-ever interest cost, lowest-ever D/E, and best-in-cycle cash conversion. The five-year compound is the cleanest in the listed Indian CDMO space.

4. Industry & Competition — Peer Comparison

The Indian CRDMO/CDMO universe is small and tightly contested. The four names that institutional investors typically compare Sai Life against are Syngene International (the bellwether), Divi's Laboratories (the gold-standard API manufacturer), Laurus Labs (the fermentation-led peer) and Piramal Pharma (the integrated complex). Below is the consolidated peer comparison table using Screener.in data (current as of the close on the reference date).

Peer Comparison Table

Observations from the peer table:

1. Size context: Sai Life at ₹25,855 Cr market cap is the third-largest pure-play CDMO in the listed Indian universe by market cap, ahead of Syngene and Piramal Pharma but well behind Divi's and Laurus. However, on a revenue basis, Sai Life is the smallest of the five — ₹2,153 Cr versus ₹10,388 Cr for Divi's and ₹6,089 Cr for Laurus. This is a "smaller revenue, larger market-cap" setup, which is what a premium multiple implies. The market is pricing Sai Life for its growth rate and asset quality, not its absolute size.

2. Growth differentiation: Sai Life's +31% sales growth in FY26 is materially ahead of the peer median. Syngene grew +1.5% as it lapped a soft biologics year, Divi's grew +13%, Laurus +17% and Piramal Pharma actually contracted -9.5% as the consumer-healthcare business got divested. The peer set broadly shows that Indian CDMOs have decelerated off the COVID-era highs, but Sai Life has accelerated in FY26 — an unusual and attractive signal.

3. Multiple inflation: Sai Life's 75.6x P/E is the second-highest in the peer set after Laurus Labs (101x). Syngene trades at 51.2x, Divi's at 66.2x and Piramal Pharma at 28.2x. The premium is being assigned to growth and asset quality (ROCE 19.2%, debt-free, strong FCF trajectory). On a PEG basis, however, the picture changes. With a 5-year profit CAGR of 114%, the PEG ratio of Sai Life is below 1.0 — making it one of the cheaper growth stories in the pharma-services universe.

4. Capital efficiency: Sai Life's 19.2% ROCE is the second-highest in the peer set, behind only Divi's Labs (22.4%). That said, the company has only just emerged from its capex cycle and the marginal ROIC is higher than the 19.2% blended number suggests. Syngene's 10% ROCE and Piramal's 12.1% are lower because of their larger fixed-cost base and integration drag.

5. Balance sheet quality: Sai Life is now near-debt-free with ₹223 Cr of borrowings against ₹2,508 Cr of equity. Laurus Labs is also largely debt-free. Syngene carries a small net cash position. Divi's Labs is famously debt-free. Piramal Pharma is the most levered. Sai Life's balance-sheet quality now matches the best in the peer set.

6. Industry tailwinds: The global pharmaceutical outsourcing market is sized at approximately USD 200 Bn and is growing at 7-8% CAGR. The Indian CRDMO sub-segment is growing faster at 12-15% CAGR due to China+1, the patent-cliff wave (2025-2030 is a "patent-cliff super-cycle" with USD 200 Bn+ of branded revenue coming off-patent), and the rise of complex modalities (peptides, HPAPIs, ADCs, oligonucleotides) where India has a cost-arbitrage advantage. Sai Life is exposed to all three vectors.

7. Customer overlap: All five companies serve broadly the same innovator customer base — large US, EU and Japanese pharma companies. Sai Life and Syngene have the most direct overlap in the discovery and development services layer. Divi's, Laurus and Piramal Pharma are heavier on the API manufacturing side. Sai Life's differentiation is the integrated "molecule-to-commercial" service offering and the peptide/HPAPI capability that is becoming a bottleneck in the global supply chain.

Valuation verdict on the peer set: Sai Life is the most expensive by absolute P/E but one of the most reasonable on PEG. The closest comparable in style and growth is Syngene (which trades at a discount likely because of the slower FY26 growth). For an investor, the trade-off is: pay 75x earnings today for 30%+ growth and a debt-free balance sheet, or wait for a multiple compression. The latter is more likely to come from a derating of the sector than from a re-rating of Sai Life specifically.

5. DCF Valuation Framework

Discounted Cash Flow (DCF) is the right framework to value a CRDMO like Sai Life because of the high operating leverage and long-duration cash flows. We construct a five-year explicit forecast (FY27 to FY31) plus a terminal value. All numbers are in ₹ Crores unless stated.

DCF Assumptions Table

Free Cash Flow Projection Table

Terminal value calculation: FCFF(terminal year) × (1+g) / (WACC − g) = 836 × 1.05 / (0.11 − 0.05) = ₹8,552 Cr. Discounted back 5 years: ₹5,071 Cr.

Valuation Output Table

Sensitivity Table — Fair Value per Share (₹)

The base-case DCF yields a fair value of ₹485 per share — meaningfully below the current market price of ₹1,218.90. This is the most important tension in the analysis. Three observations help reconcile the gap:

1. Bull-case DCF: If terminal growth is 7% and WACC is 9% (justifiable for a debt-free, 30%-growth franchise), the fair value rises to ₹1,058 per share — closer to but still below the market price. The market is essentially pricing Sai Life in the bull-case corner of the DCF distribution.

2. Market is paying for option value: The 2,500+bps expansion in OPM (from 14% to 28%) over five years is not in steady-state. A 32-35% OPM, achievable at scale as commercial supply mix rises, would lift the DCF fair value into the ₹700-900 range. The market is paying for that option.

3. EV/EBITDA cross-check: Sai Life's enterprise value at the current market price is approximately ₹24,200 Cr (₹25,855 Cr equity minus ₹1,650 Cr net cash). FY26 EBIT of ₹600 Cr plus depreciation of ₹152 Cr implies an EV/EBITDA of ~32x. The peer median EV/EBITDA for Indian CDMOs is 25-28x. Sai Life trades at a 15-25% premium to that — consistent with the growth differential and not excessive.

Synthesis: The DCF says "₹485-700" is the fundamental fair value depending on assumptions. The market is paying "₹1,219". The gap is the implicit growth option. Investors should size the position recognising that 25-40% of the current price is option premium, not steady-state DCF.

6. Shareholding Pattern

The shareholding pattern of Sai Life Sciences is one of the cleanest in the listed Indian mid-cap space, with a global private equity anchor, a deep domestic institutional base and a gradually declining promoter stake. Below is the most recent quarterly shareholding pattern from Screener.in.

Shareholding Pattern Table (% of paid-up capital)

Three structural observations:

First, the TPG anchor. Global private equity major TPG holds a meaningful stake — directly and through the promoter group. The promoter holding of 34.61% in March 2026 is dominated by the Kanumuri family and TPG-affiliated entities. TPG's pre-IPO investment was at a sub-₹200 per share cost basis; at the current price of ₹1,218.90, the marks are very attractive. The TPG anchor is what gives the company its institutional governance and global pharma client network — TPG's pharma-services portfolio includes several other CRDMO assets that share customer referrals and best practices.

Second, the FII + DII rotation. In the eight quarters shown, FIIs have grown from 11.72% to 21.17% and DIIs from 11.95% to 31.54%. Combined institutional holding (FII + DII) is now 52.71% of the company, up from 23.67% in Dec 2024. The retail float has correspondingly shrunk from 41.08% to 12.69%. This is a textbook mid-cap "institutionalisation" trajectory: smart money is accumulating while retail is exiting, and the public float is becoming scarcer. The number of shareholders has come down from 1.81 lakh in Dec 2024 to 1.18 lakh in March 2026 — a 35% consolidation in the shareholder base.

Third, promoter holding is steady around 35% and has only modestly declined as some pre-IPO shareholders (TPG and other PE investors) monetise. The promoter pledge, as of the latest disclosures, is nil — i.e., there is no leverage on the promoter stake. This is unusually clean for a recently listed Indian mid-cap.

The combination — debt-free, institutional-heavy shareholding, global PE anchor, no promoter pledge — gives Sai Life a quality-of-ownership profile that few Indian mid-caps can match. It also means price-discovery is increasingly in the hands of large institutional investors, which should dampen volatility over time.

7. Key Risks

Sai Life's bull case is strong, but no investment is one-sided. The following risks deserve careful weighting.

1. Customer concentration risk: As a CRDMO, Sai Life derives a meaningful share of revenue from a small number of strategic accounts. Loss of a top-5 customer, or a major product discontinuation by a key customer, could materially impact revenue. Mitigation: the customer base is gradually widening as new programs convert from clinical to commercial. The 10-quarter sales growth from ₹264 Cr to ₹594 Cr without a single step-down quarter (other than the Q1 FY25 inventory blip) suggests the customer base is structurally diversified.

2. Capex execution risk: Sai Life has ₹270 Cr of CWIP on the balance sheet as of March 2026 and a forward capex plan of ₹400-500 Cr over FY27-FY28. Delays in commissioning new blocks (HPAPI, peptides, injectables) or cost overruns could compress ROIC. Mitigation: the management team has a credible track record of delivering capacity on time, and the de-levered balance sheet means the company is not financially stressed by delays.

3. Pricing pressure and China+1 dynamics: Indian CRDMOs benefit from the China+1 theme, but China is not standing still. Chinese API manufacturers are also investing in regulated-market compliance, and pricing in the CDMO space is competitive. A reversal of the China+1 theme (geopolitical thaw, US-China trade deal) could compress Sai Life's pricing power.

4. Regulatory risk: Sai Life's manufacturing facilities are subject to US FDA, EU EMA, Japan PMDA and other regulator inspections. A Form 483 observation or a Warning Letter on a key facility would have an outsized impact on share price. Mitigation: Sai Life has a clean regulatory track record with no warning letters historically.

5. Currency risk: The vast majority of revenue is USD-denominated, while a significant portion of cost (Indian scientist salaries, INR-denominated expenses) is INR-denominated. A 5% INR appreciation versus the USD could compress reported margins by 200-300bps. Mitigation: the company has a partial natural hedge (USD-denominated costs in the US subsidiaries) and uses limited forward-cover.

6. Valuation risk: The single largest risk to a buyer at ₹1,218.90 is multiple compression. The stock is trading at 75.6x P/E and 10x P/B, both of which are at the upper end of the historical range. A 20% multiple derating (to ~60x P/E) on flat earnings would deliver a -20% return even if the business does well. The DCF in Section 5 confirms that 25-40% of the current price is option premium, not steady-state value.

7. TPG exit risk: TPG, as the pre-IPO anchor, may look to monetise its residual stake over the next 12-24 months. A block deal by TPG would create a temporary supply-demand imbalance and could weigh on the share price. This is a known overhang and is partially priced in.

8. Working capital and cash flow volatility: Days payable has swung from 114 in FY24 to 270 in FY25 to 200 in FY26. Days inventory has ranged from 73 to 185. These swings can create quarter-to-quarter cash flow volatility that may unnerve less-patient investors.

The risk-reward at ₹1,218.90 is therefore balanced but not asymmetric — the upside requires continued execution and a sustained global pharma R&D environment, while the downside is a multiple compression scenario. Risk management is best done via position sizing and entry-price discipline.

8. What This Means for Investors

For investors evaluating Sai Life Sciences, the actionable conclusion of this report is structured below.

Investment Thesis Matrix

For long-term compounders (5-year horizon): Sai Life Sciences is a high-quality compounder with a credible path to ₹3,500-4,500 Cr revenue and ₹800-1,000 Cr net profit by FY29. At even a 50x P/E (a discount to current), that implies a ₹2,000-2,400 per share target — a 70-100% upside from current levels. Position sizing should reflect the volatility of growth stocks.

For tactical investors (6-12 month horizon): The stock has already run +58.2% in the last year. A pullback to the ₹1,000-1,100 zone (around the 50-DMA or 200-DMA) would offer a better risk-reward entry. Use the 52-week low of ₹900 as a hard stop-loss reference.

For SIP-style allocators: Allocate Sai Life as a 2-3% weight in a healthcare or pharma-services portfolio, paired with Syngene (more defensive) and Divi's Labs (more profitable). The combination gives diversified exposure to the Indian CDMO theme.

Key catalysts to watch:

1. Q1 FY27 results (July-August 2026) — the first quarter post the strong Q4 FY26. Sequential momentum and YoY growth will be the key tell.
2. Capex updates — the peptide and HPAPI facilities should commission in FY27. Each facility adds ₹150-250 Cr of incremental annual revenue at maturity.
3. TPG stake actions — any disclosure on TPG's residual stake will be a price catalyst (positive if orderly, negative if block-sale overhang).
4. FDA inspections — Sai Life's next US FDA inspection cycle is a key regulatory milestone.
5. Management guidance — at the next earnings call, watch for commentary on FY27 revenue growth and the capex pipeline.

Valuation summary:

The probability-weighted fair value of approximately ₹1,015 per share is 17% below the current market price of ₹1,218.90. This is a mildly overvalued setup with strong business fundamentals. The investment proposition is therefore: "Own this business, but be price-sensitive on the entry."

Final investment view: HOLD with positive bias. Investors who already own the stock should continue to hold given the structural quality of the franchise. Investors without a position should wait for a 10-15% pullback to the ₹1,050-1,100 zone for a more attractive risk-reward. Avoid FOMO-chasing at current levels, but do not underweight the sector on the basis of headline multiple alone — the underlying business deserves a place in any Indian CRDMO allocation.

9. Disclaimer

This research article is for informational and educational purposes only. It does not constitute investment advice, a recommendation to buy or sell any security, or an offer to provide investment-banking or advisory services. The author / publisher of this article (NiftyBrief) and its affiliates may hold positions in the securities mentioned. All financial data is sourced from publicly available filings on the BSE / NSE, Screener.in and the company's investor-relations disclosures. While reasonable care has been taken in data compilation, no warranty is made as to the accuracy, completeness or timeliness of the information. Past performance is not indicative of future results. Equity investments are subject to market risks; readers should consult a SEBI-registered investment advisor before making any investment decisions. The views expressed are those of the author as of the publication date and are subject to change without notice. All trademarks and intellectual property are the property of their respective owners.

Published by NiftyBrief | AI-Generated Equity Research | BSE-Verified Data | Reference Date: 12 June 2026